Clinical Trials

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations


Study ID
Janssen 42756493BLC2002

NCT Number
NCT03473743 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0084

Principle Investigator
Dr. Martin Gutierrez

Phase
I/II

Sponsor
Janssen Research & Development


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now